NeuroOne Medical Technologies (NeuroOne Medical Technologies) Change In Receivables : $-0.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is NeuroOne Medical Technologies Change In Receivables?

NeuroOne Medical Technologies's change in receivables for the quarter that ended in Mar. 2024 was $-0.01 Mil. It means NeuroOne Medical Technologies's Accounts Receivable increased by $0.01 Mil from Dec. 2023 to Mar. 2024 .

NeuroOne Medical Technologies's change in receivables for the fiscal year that ended in Sep. 2023 was $0.03 Mil. It means NeuroOne Medical Technologies's Accounts Receivable declined by $0.03 Mil from Sep. 2022 to Sep. 2023 .

NeuroOne Medical Technologies's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.56 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. NeuroOne Medical Technologies's Days Sales Outstanding for the three months ended in Mar. 2024 was 36.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. NeuroOne Medical Technologies's liquidation value for the three months ended in Mar. 2024 was $1.97 Mil.

NeuroOne Medical Technologies Change In Receivables Historical Data

The historical data trend for NeuroOne Medical Technologies's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroOne Medical Technologies Change In Receivables Chart

NeuroOne Medical Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

-0.05

0.02

0.03

NeuroOne Medical Technologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.12	0.21	-	-0.54	-0.01

NeuroOne Medical Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.34 Mil.

NeuroOne Medical Technologies (NAS:NMTC) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

NeuroOne Medical Technologies's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.556	/	1.377	*	91
=	36.84

2. In Ben Graham's calculation of liquidation value, NeuroOne Medical Technologies's accounts receivable are only considered to be worth 75% of book value:

NeuroOne Medical Technologies's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.435	-	1.54	+	0.75 * 0.556	+	0.5 * 1.312
=	1.97

NeuroOne Medical Technologies Change In Receivables Related Terms

Thank you for viewing the detailed overview of NeuroOne Medical Technologies's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroOne Medical Technologies (NeuroOne Medical Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroOne Medical Technologies Corp (NAS:NMTC) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7599 Anagram Dr., Eden Prairie, MN, USA, 55344

Website

https://www.n1mtc.com

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Executives

Mark Christianson	10 percent owner, officer: VP, Business Dev and Marketing	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Ronald W. Mcclurg	officer: Chief Financial Officer	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
David A Rosa	director, officer: CEO and President	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Hijaz Haris	officer: VP of Marketing	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DR, EDEN PRAIRIE MN 55344
Morgan C. Frank	10 percent owner	2 CALLE NAIRN, UNIT 701, SAN JUAN PR 00907
Manchester Management Co Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02110
Manchester Explorer, L.p.	10 percent owner	MANCHESTER MANAGEMENT COMPANY, L.L.C, 3 WEST HILL PLACE, Boston ma 02114
James E Besser	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Manchester Management Pr, Llc	10 percent owner	3 WEST HILL PLACE, BOSTON MA 02114
Edward Andrle	director	C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE MN 55344
Wade Fredrickson	10 percent owner	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347
Steve Mertens	officer: Chief Technology Officer	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Scott Heuler	officer: Vice President of Sales	10901 RED CIRCLE DR., SUITE 150, MINNETONKA MN 55343
Paul Buckman	director	12988 VALLEY VIEW RD, EDEN PRAIRIE MN 55402
Suraj Kalia	director	10006 LIATRIS LANE, EDEN PRAIRIE MN 55347